Slide 1: Quarterly Activity and Cash Flow Report
ImpediMed Limited Suite 31C, 12-18 Tryon Rd Lindfield NSW 2070 Australia E: investorrelations@impedimed.com W : impedimed.com 30 October 2025 Companies Announcements Office Australian Securities Exchange Quarterly Activity and Cash Flow Report Key highlights for the first quarter • Revenue of A$3.6
Slide 2: Key sales and financial metrics
The launch of SOZO Pro, the only FDA-cleared BIS device for patients with cardiac implantable devices, strengthens the Company’s competitive edge and enables scalable growth with our existing infrastructure. Heart Failure and Body Composition launches have been initiated. In Heart Failure, commercia
Slide 3: Cash balance, reimbursement and Investor Hub
As at 30 September 2025, ImpediMed has a total cash balance of A$23.0 million comprising A$2.5 million cash in bank and A$20.5 million in term deposits. Strengthening of the Australian dollar resulted in an unrealised FX loss of $0.7million. The cash balance includes US$5.0 million from Tranche 2 of
Slide 4: Investor conference call
Investor conference call Investors are invited to join a webinar hosted by CEO and Managing Director, Dr Parmjot Bains and CFO and Executive Director, McGregor Grant at 9.00am AEDT on Thursday 30 October 2025. To pre-register, please follow this link: https://investors.impedimed.com/webinars/lyaLKP-
Slide 5: About ImpediMed
About ImpediMed Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health. ImpediMed produces the SOZO® Digital Health Platform,
Slide 6: Appendix 4C Quarterly cash flow report
Rule 4.7B Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B Name of entity ImpediMed Limited ABN Quarter ended (“current quarter”) 65 089 705 144 30 September 2025 Consolidated statement of cash flows Current quarter Year to date $A’000 $A’000 1. Cash flows from operat
Slide 7: Consolidated statement of cash flows
Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B Consolidated statement of cash flows Current quarter Year to date $A’000 $A’000 2.2 Proceeds from disposal of: (a) entities - - (b) businesses - - (c) property, plant and equipment - - (d) investments - - (e) intellectu
Slide 8: Consolidated statement of cash flows and cash reconciliation
Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B Consolidated statement of cash flows Current quarter Year to date $A’000 $A’000 4.4 Net cash from / (used in) financing activities 6,962 6,962 (item 3.10 above) 4.5 Effect of movement in exchange rates on (694) (694) ca
Slide 9: Financing facilities
Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B 7. Financing facilities Total facility Amount drawn at Note: the term “facility’ includes all forms of financing amount at quarter quarter end arrangements available to the entity. end $A’000 Add notes as necessary for
Slide 10: Compliance statement
Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B Compliance statement 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A. 2 This statement gives a true and fair view of the matters disclosed. D